Page last updated: 2024-09-04
docetaxel anhydrous and bms 754807
docetaxel anhydrous has been researched along with bms 754807 in 1 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (bms 754807) | Trials (bms 754807) | Recent Studies (post-2010) (bms 754807) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 55 | 0 | 46 |
Protein Interaction Comparison
Protein | Taxonomy | docetaxel anhydrous (IC50) | bms 754807 (IC50) |
---|---|---|---|
G1/S-specific cyclin-E2 | Homo sapiens (human) | 1.035 | |
High affinity nerve growth factor receptor | Homo sapiens (human) | 0.007 | |
Insulin receptor | Homo sapiens (human) | 0.0017 | |
Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.0036 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 7 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.0021 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 1.035 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 1.035 | |
RAC-alpha serine/threonine-protein kinase | Mus musculus (house mouse) | 0.022 | |
BDNF/NT-3 growth factors receptor | Homo sapiens (human) | 0.004 | |
Insulin-like growth factor 1 receptor | Mus musculus (house mouse) | 0.013 | |
Serine/threonine-protein kinase LMTK3 | Homo sapiens (human) | 3.161 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Carboni, JM; Chan, BT; Chang, JC; Creighton, CJ; Gottardis, MM; Hilsenbeck, SG; Huang, F; Lee, AV; Lewis, MT; Litzenburger, BC; Rimawi, MF; Tsimelzon, A; Wang, T | 1 |
Other Studies
1 other study(ies) available for docetaxel anhydrous and bms 754807
Article | Year |
---|---|
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Insulin-Like Growth Factor I; Mice; Mice, Inbred NOD; Mice, SCID; NIH 3T3 Cells; Pyrazoles; Receptor, ErbB-2; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Triazines; Xenograft Model Antitumor Assays | 2011 |